Liabilities in USD of General Enterprise Ventures, Inc. from Q4 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
Summary
General Enterprise Ventures, Inc. quarterly Liabilities history and change rate from Q4 2019 to Q3 2025.
  • General Enterprise Ventures, Inc. Liabilities for the quarter ending 30 Sep 2025 was $3.75M, a 77.7% increase year-over-year.
Liabilities, Quarterly (USD)
Liabilities, YoY Quarterly Change (%)

General Enterprise Ventures, Inc. Quarterly Liabilities (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $3.75M +$1.64M +77.7% 30 Sep 2025 10-Q 12 Nov 2025
Q2 2025 $6.5M +$4.36M +204% 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 $4.96M +$3.47M +233% 31 Mar 2025 10-Q 20 May 2025
Q4 2024 $2.16M +$494K +29.6% 31 Dec 2024 10-Q 12 Nov 2025
Q3 2024 $2.11M +$320K +17.9% 30 Sep 2024 10-Q 18 Nov 2024
Q2 2024 $2.14M +$684K +47% 30 Jun 2024 10-Q 19 Aug 2024
Q1 2024 $1.49M +$175K +13.3% 31 Mar 2024 10-Q/A 12 Aug 2024
Q4 2023 $1.67M +$607K +57.2% 31 Dec 2023 10-K 31 Mar 2025
Q3 2023 $1.79M +$971K +118% 30 Sep 2023 10-Q 15 Nov 2023
Q2 2023 $1.45M +$877K +152% 30 Jun 2023 10-Q 16 Aug 2023
Q1 2023 $1.31M +$892K +211% 31 Mar 2023 10-Q 15 May 2023
Q4 2022 $1.06M +$678K +177% 31 Dec 2022 10-K/A 30 Jul 2024
Q3 2022 $822K +$728K +772% 30 Sep 2022 10-Q 10 Nov 2022
Q2 2022 $577K +$500K +648% 30 Jun 2022 10-Q 22 Aug 2022
Q1 2022 $423K +$414K +4423% 31 Mar 2022 10-Q 16 May 2022
Q4 2021 $383K +$374K +3995% 31 Dec 2021 10-K 31 Mar 2023
Q3 2021 $94.3K 30 Sep 2021 10-Q/A 22 Mar 2022
Q2 2021 $77.1K 30 Jun 2021 10-Q 08 Oct 2021
Q1 2021 $9.36K 31 Mar 2021 10-Q 04 Oct 2021
Q4 2020 $9.36K +$9.36K 31 Dec 2020 10-K 12 Apr 2022
Q4 2019 $0 31 Dec 2019 10-K 29 Sep 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.